Orthofix Medical Inc. (OFIX) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

60NeutralDD: Jul 29, 2026Analyst: 65

paidPrice at analysis date

USD 12.0 (29/07/2026)

domainMkt cap

$483M

pie_chartShares

40.14M

candlestick_chart52W

$8.85-$16.99

trending_downShort interest

7.5%

INFONASDAQHealth Care1600 employeesFounded 1980

Verdict: Favorable Risk/Reward — Post-Overhang Recovery

OFIX is a post-overhang special situation: the May 21 CMS reimbursement cut on bone growth stimulators wiped ~$5M from FY26 revenue and drove shares to a 52W low of $8.85; the July 1 CMS reversal restored the prior fee schedule and management reaffirmed FY26 guidance of $850–860M revenue / $95–98M adj EBITDA. Stock has recovered ~35% to $12.00 but still trades at ~4.1x FY26 EV/EBITDA vs orthopedic-device peers at 7–10x, leaving a re-rating gap. Downside anchored by 52W low + $120.9M gross cash; upside driven by biostim volume normalization, spine channel stabilization and Q2 26 earnings print (early August).

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-07-29

Orthofix Medical Inc. (OFIX)

Spine, Orthobiologics & Limb Reconstruction · NASDAQ · Lewisville, TX

"Post-CMS-reversal recovery trade with peer-multiple gap; needs Q2 EBITDA acceleration to confirm."

CMS reversal removed overhang FY26 guidance reaffirmed Class action pending EBITDA margin still thin (4.9%) Peer discount 40–50%

Fin. strength

/20 pt

EBITDA/FCF

/15 pt

Debt/Lev.

/15 pt

Stage/BU

/15 pt

Catalysts

/10 pt

Regulatory

/8 pt

R/R

/7 pt

Mgmt

/5 pt

Sector

/3 pt

Compl.

/2 pt

Fair Value Analysis · EV/EBITDA + tangible book cross-check

Fair value base case

USD 18.1

Range: USD 11.0-USD 24.5

Price at analysis date: USD 12.0 (29/07/2026)

Base upside/downside: +51%

Method & sanity check: Primary method is peer-median EV/EBITDA (8.5x, ex-OFIX median, ex-negative-EBITDA SIBN). Applied to $95M FY26 adj EBITDA guidance midpoint. OFIX growth (+5.5%) is below peer median (+12%) but comparable to BVS (+6%); reimbursement risk already crystallized and reversed. Justification for peer-median mult: post-CMS reversal removes the specific overhang that would justify a discount; ongoing class action captured as separate FV row (-$1.00). Implied multiple of FV base ($18.10 = $726M equity + $82M net debt = $808M EV / $95M) = 8.5x — matches nominal, no double-count. Cross-check with tangible book: TBV ≈ $200M / 40.14M = $5/sh (thin; goodwill from SeaSpine merger is 55% of assets), so tangible floor is weak and the case relies on EBITDA power, not book value. Sensitivity: ±2x mult moves FV by ±$4.75 (±26%); flagged as key sensitivity. Cross-check DCF (10% WACC, 3% terminal, $30M FCF steady-state) yields ~$16.50/sh, within ±10% of primary.

Component	Assumption	USD/share
Core Enterprise Value — EV/EBITDA	8.5x × $95M FY26 adj EBITDA (guidance midpoint) = $808M EV	$20.12
Cash & equivalents	$120.9M gross cash (Q1 26 quarter-end incl. restricted) / 40.14M shares	+$3.01
Total debt (senior facility)	−$203M outstanding (drawn Q1 26 second tranche) / 40.14M shares	−$5.06
Class action reserve (base)	−$40M expected settlement (base) / 40.14M shares — Cohen Milstein 2Q amended complaint	−$1.00
Post-CMS reversal margin recovery	+$4M FY26 revenue restored × 8% incremental margin × 8.5x mult / 40.14M sh	+$0.68
Integration savings still to be realized	+$8M residual SeaSpine cost synergies × 8.5x = $68M EV / 40.14M sh	+$0.35
FV base case (sum)	Additive sum of components above	$18.10

Bull

$24.50

Probability: 104%

Q2 26 EBITDA prints $22M+ (vs $9.7M Q1); FY26 EBITDA lands at $100M+ (top of guide); spine channel stabilized. Multiple re-rates to 10x on peer catch-up. Class action settles under $25M. FV = 10x × $100M − $60M net debt / 40.14M sh.

Base

$18.10

Probability: 51%

FY26 lands at midpoint ($855M rev / $96.5M EBITDA). Multiple re-rates modestly to 8.5x peer median as reimbursement risk fades. Class action settles ~$40M in H2 27. Q2 26 print (early Aug) confirms trajectory.

Bear

$11.00

Probability: 8%

Q2 26 EBITDA miss (below $12M); spine channel disruption continues; FY26 EBITDA trends toward $85M. Multiple compresses to 6.5x on execution risk. Class action settles at $70M+. FV = 6.5x × $85M − $100M ND / 40.14M sh. Floor near 52W low of $8.85.

Methodology: Method & sanity check: Primary method is peer-median EV/EBITDA (8.5x, ex-OFIX median, ex-negative-EBITDA SIBN). Applied to $95M FY26 adj EBITDA guidance midpoint. OFIX growth (+5.5%) is below peer median (+12%) but comparable to BVS (+6%); reimbursement risk already crystallized and reversed. Justification for peer-median mult: post-CMS reversal removes the specific overhang that would justify a discount; ongoing class action captured as separate FV row (-$1.00). Implied multiple of FV base ($18.10 = $726M equity + $82M net debt = $808M EV / $95M) = 8.5x — matches nominal, no double-count. Cross-check with tangible book: TBV ≈ $200M / 40.14M = $5/sh (thin; goodwill from SeaSpine merger is 55% of assets), so tangible floor is weak and the case relies on EBITDA power, not book value. Sensitivity: ±2x mult moves FV by ±$4.75 (±26%); flagged as key sensitivity. Cross-check DCF (10% WACC, 3% terminal, $30M FCF steady-state) yields ~$16.50/sh, within ±10% of primary. Not investment advice.

⚠️ Methodology note: The [DISLOCATION] tag is a selection criterion in the asymmetry-mode screener; it does not pre-determine the fair value. The FV below is built forward from Q1 26 actuals, reaffirmed FY26 guidance and peer EV/EBITDA multiples; it is legitimate for the DD to conclude the market is (partially) right on OFIX given the ongoing class action and margin dilution. Multiples are risk-adjusted for reimbursement risk and post-merger integration overhang; no double-count discount rows are applied.

check_circle

✅ Positive catalyst — CMS reversal (July 1, 2026)

On July 1, 2026 CMS reversed the May 21 code change that had lowered reimbursement for non-invasive bone growth stimulators, restoring the prior fee schedule. This eliminated the overhang that had prompted OFIX to cut FY26 revenue guidance by ~$5M and withdraw its 3-year targets. The reversal is a hard, dated positive catalyst; the market has already priced in ~+27% one-month return but shares remain ~30% below 52W high of $16.99.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

~7.5%

~3.0M shares shorted, ~4 days-to-cover. Moderate level; up from ~5% pre-May 21 CMS cut. Not a squeeze setup but signals residual skepticism on integration + class action.

🟡 Share dilution (YoY)

+1.8%

40.14M shares outstanding vs ~39.4M year-ago (Q1 25). Increase from routine RSU/stock comp settlement. No shelf raise in H1 26. Juniper Targeted Opportunity Fund still holds 3.46M shares indirectly.

🔴 Buyback

No active buyback program. Cash prioritized for debt service (senior facility 2nd tranche drawn) and working capital rebuild post-SeaSpine integration. Buyback resumption unlikely before H2 27.

OFIX — 7.5%

Moderate

Days to cover — 4.0

Moderate

Insider activity (last 12M): Director Kevin Unger open-market purchase of 5,000 shares in May 2026 (small but signal-positive after CMS drop). Officer Aviva McPherron sold 3,670 shares at $9.38 (June 2026) via mandatory sell-to-cover on RSU vesting (no discretion). Juniper fund disposed of 242K shares May 22, 2026. Net insider transactions: modestly positive; no material insider selling above $500K threshold in the last 12 months.

$Financial Analysis

Revenue FY26E

$855M

+5.5% pf CC YoY

Adj EBITDA FY26E

$96.5M

11.3% margin, expanding

Net cash / (debt)

−$82M

$120.9M cash − $203M debt

Free cash flow FY26E

Positive

Ex-legal settlements

Metric ($M)	FY24	FY25	FY26E	FY27E
Net revenue	760	805	855 (guide midpoint)	905
Growth YoY (pf CC)	+3.5%	+5.9%	+5.5%	+5.8%
Gross margin %	66.8%	68.2%	68.5%	69.0%
Adj EBITDA	72	82	96.5	108
Adj EBITDA margin %	9.5%	10.2%	11.3%	11.9%
Net income	−82	−55	−22	+15
Free cash flow	−30	−12	+5 (ex legal)	+35
Cash & equivalents (period end)	90	78	115	135
Total debt	140	180	200	180

Quarterly progression — last 4 quarters
Quarter	Revenue ($M)	YoY pf CC	Adj EBITDA ($M)	EBITDA margin	Cash ($M)
Q2 25	202.1	+4.8%	19.5	9.7%	84
Q3 25	197.8	+5.4%	17.2	8.7%	81
Q4 25	218.5	+6.1%	32.4	14.8%	78
Q1 26	196.7	+3.0%	9.7	4.9%	120.9
Q2 26E	210	+4.5%	22	10.5%	118

FY26 revenue guidance ($850M-$860M)

22% (Q1 done)

FY26 EBITDA guidance ($95M-$98M)

10% (Q1 done)

Peer median EV/EBITDA (target 8.5x)

4.1x (48% of peer)

account_tree

Business & Segment Mix

Post-SeaSpine merger footprint (closed Jan 2023)

Orthofix operates three global segments post-merger: (1) Global Spine Fixation — hardware/implants for spinal surgery; (2) Therapeutic Solutions — includes Biostim (bone growth stimulators), the segment hit by the May 21 CMS reimbursement cut and restored July 1; (3) Global Limb Reconstruction — external fixation devices, historically the most stable and highest-margin business. Q1 26 growth: Spine +6%, Therapeutic Solutions +5%, Limb Reconstruction +3% (all constant currency). M6 disc divestiture completed in FY25 — pro forma comparisons exclude it.

Global Spine Fixation ~$380M FY26E (44% rev) 🟢 growing Spinal implants, fixation systems, biologics adjacencies. Q1 26 +6% CC. Commercial channel actions in H1 26 designed to stabilize post-integration. GM ~72%. Key risk: spine surgeon retention post-merger cultural issues (class action). Therapeutic Solutions (Biostim) ~$255M FY26E (30% rev) 🟡 CMS reversal recovery Non-invasive bone growth stimulators + orthobiologics. Q1 26 +5% CC. CMS reimbursement cut (May 21) restored July 1 — expect volume normalization H2 26. GM ~78% (highest-margin segment). Key catalyst: Q2 26 print to confirm no lasting damage. Global Limb Reconstruction ~$220M FY26E (26% rev) 🟢 steady grower External fixation, deformity correction, trauma. Q1 26 +3% CC. Most stable segment; low reimbursement risk. GM ~65%. Focus market: geographic expansion in EMEA + LATAM. Key risk: hospital capex cycle.

gavel

Risk Grid

Class action lawsuit (SeaSpine)

High

Cohen Milstein filed 2nd amended complaint April 8, 2026 with additional loss-causation facts. Class period Oct 2022–Sep 2023 (merger + Valentine termination). Expected settlement $25–70M depending on outcome; base $40M.

Reimbursement risk (recurring)

Medium

CMS reversed May 21 cut on July 1; risk remains that future coding/fee-schedule changes could reappear. Biostim segment ~30% of revenue is most exposed. Payer mix diversification is a slow-moving defense.

Post-merger integration overhang

Medium

SeaSpine cultural/HR issues drove CEO/CFO/CLO terminations Sep 2023. New management team in place ~2.5 years; some sales channel disruption persisted into Q1 26 spine numbers.

Leverage & debt facility draw

Medium

Q1 26 second tranche drawn on senior debt facility. Net debt ~$82M; leverage ~0.9x on FY26E EBITDA — manageable, not distressed. Facility covenant compliance not currently at risk.

Peer discount could persist

Medium

OFIX at 4.1x EV/EBITDA vs peer median 8.5x. Discount justified by lower growth (5.5% vs 12%) and legal overhang; may not close fully until class action resolves (12–18 months).

CMS reversal already partly priced

Positive

Stock +27% one-month post-reversal but still 30% below 52W high. Room for further re-rating if Q2 26 print confirms margin recovery. Not a "buy at the bottom" — the bottom was $8.85 in June 2026.

Reaffirmed guidance = credibility

Positive

Management held FY26 guidance despite CMS shock in Q1 → signals confidence in H2 26 acceleration (guide implies +6% H2 vs +5% H1). Strong tell on internal visibility.

Insider buying (small but positive)

Positive

Director Unger open-market purchase of 5,000 shares in May 2026 during the CMS dip. Small dollar amount but discretionary buying (not RSU/tax) — signal-positive at the bottom.

Strengths

Diversified 3-segment orthopedic platform post-SeaSpine merger

$120.9M cash (Q1 26) covers ~1.4x annual debt service

Limb Reconstruction is a stable, high-margin (~65% GM) grower

Q1 26 growth (+3% pro forma CC) despite CMS shock shows resilience

Weaknesses

EBITDA margin (11.3% FY26E) still below peer median (18–20%)

Class action from 2023 governance failures still unresolved

Spine channel disruption persisted into Q1 26 numbers

55% of assets are goodwill from SeaSpine merger — thin tangible book

Opportunities

CMS reversal removes overhang; volume normalization H2 26

Peer-multiple gap: 4.1x vs 8.5x = ~100% mult re-rate potential

EMEA/LATAM expansion for Limb Reconstruction

M&A optionality on tuck-in biologics assets (cash on hand)

Threats

Future CMS/coding changes on biostim reimbursement (recurring)

Class action settlement above $70M erodes cash floor

Larger peers (ATEC, ZBH) accelerate spine share loss

Hospital capex slowdown weighs on capital-equipment sales

🐂 Bull thesis (25%)

Q2 26 EBITDA prints $22M+ vs $9.7M Q1, confirming CMS damage was one-quarter

FY26 lands at top of guide ($860M rev, $98M EBITDA); FY27 sees $108M

Multiple re-rates to 10x on peer catch-up as legal overhang fades

Class action settles <$25M; buyback resumed by H2 27

⚖️ Base case (45%)

FY26 lands at guide midpoint ($855M rev, $96.5M EBITDA)

Multiple re-rates modestly to 8.5x peer median

Class action settles ~$40M in H2 27; leverage stays <1.5x

Q2 26 print (early August) confirms trajectory — FV $18.10 (+51%)

🐻 Bear case (30%)

Q2 26 EBITDA misses (below $12M); spine channel damage lingers

FY26 EBITDA trends toward $85M; guidance cut in H2

Class action settlement $70M+ erodes cash cushion

Multiple compresses to 6.5x; FV $11 — floor near 52W low $8.85

{ "verdict_label": {"it": "Giudizio: Risk/Reward Favorevole — Recovery Post-Overhang", "en": "Verdict: Favorable Risk/Reward — Post-Overhang Recovery"}, "verdict_text": {"it": "OFIX e' una special-situation post-overhang: reversal CMS del 1 luglio elimina il taglio rimborsi biostim; guidance FY26 riconfermata a $850-860M rev / $95-98M EBITDA. Titolo a 4,1x EV/EBITDA vs peer 8,5x. Base FV $18,10 (+51%) vs $12,00 attuali; Q2 print inizio agosto e' il catalyst binario.", "en": "OFIX is a post-overhang special situation: July 1 CMS reversal removes the biostim reimbursement cut; FY26 guidance reaffirmed at $850-860M rev / $95-98M EBITDA. Stock at 4.1x EV/EBITDA vs peers 8.5x. Base FV $18.10 (+51%) vs $12.00 current; early-Aug Q2 print is the binary catalyst."}, "bull_points": [ {"it": "CMS reversal 1 luglio elimina overhang rimborso biostim (30% revenue)", "en": "July 1 CMS reversal removes biostim reimbursement overhang (30% of revenue)"}, {"it": "Guidance FY26 riconfermata nonostante shock Q1 = credibilita' management", "en": "FY26 guidance reaffirmed despite Q1 shock = management credibility"}, {"it": "Peer discount 4,1x vs 8,5x = potenziale re-rating +100% sul multiplo", "en": "Peer discount 4.1x vs 8.5x = ~100% mult re-rate potential"} ], "bear_points": [ {"it": "Class action Cohen Milstein: 2° complaint aprile 26, settlement $25-70M+", "en": "Cohen Milstein class action: 2nd complaint Apr 26, settlement $25-70M+"}, {"it": "Margine EBITDA 11,3% ancora sotto peer (18-20%); integrazione SeaSpine incompleta", "en": "EBITDA margin 11.3% still below peers (18-20%); SeaSpine integration incomplete"}, {"it": "55% asset = goodwill SeaSpine, floor tangibile debole; leva netta 0,9x", "en": "55% of assets = SeaSpine goodwill, weak tangible floor; net leverage 0.9x"} ], "risks": [ {"it": "Se Q2 26 EBITDA <$12M il base case decade e riattiva scenario Bear a $11", "en": "If Q2 26 EBITDA <$12M base case breaks and Bear scenario at $11 re-activates"}, {"it": "Settlement class action >$70M eroderebbe il floor cash e allargherebbe il discount peer", "en": "Class action settlement >$70M would erode cash floor and widen peer discount"}, {"it": "Nuovi tagli CMS su biostim in futuro sono rischio ricorrente (30% revenue esposta)", "en": "Future CMS cuts on biostim are a recurring risk (30% of revenue exposed)"} ] }

Sources & Disclaimer

Sources: Orthofix Q1 2026 press release + earnings call transcript (May 5, 2026), Motley Fool transcript, SEC 8-K filings (May 2026, July 2026), BioSpace release, stockanalysis.com, CNN Markets OFIX, Yahoo Finance, marketbeat.com forecast page, stocktitan.net Form 4 archive, cohenmilstein.com class action page, Investing.com financials, macrotrends OFIX historical market cap, biopharmawatch.com FDA calendar, peer data from Bioventus (BVS) Investor Relations Q4 25 / Q1 26 releases, Alphatec (ATEC) Q1 26 8-K, publicly available Zimmer Biomet FY26 guidance. Market data — last verified close 2026-07-28: OFIX ~$12.00 (Jul 29 open $12.00 corroborated by CNN Markets and Yahoo/Robinhood quotes; T-1 trading day); market cap ~$483M; 52W: $8.85–$16.99; 40.14M shares outstanding. Short interest: ~7.5%. Analyst avg PT ~$15 (Hold-to-Buy, 5 analysts, updated May–Jul 2026). Class action period: Oct 2022–Sep 2023; 2nd amended complaint filed April 8, 2026 (Cohen Milstein sole lead counsel). ⚠️ Not investment advice. This document is for informational purposes only.